Maxim Group Maintains Buy on Viking Therapeutics, Raises Price Target to $15
Maxim Group analyst Naz Rahman maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and raises the price target from $10 to $15.
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday’s Mid-Day Session
Gainers
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Madrigal Pharmaceuticals, Cerevel Therapeutics And Some Other Big Stocks Moving Higher On Monday
U.S. stocks traded mixed, with the Nasdaq Composite dropping around 90 points on Monday. Here are some big stocks recording gains in today’s session.
US Stocks Slightly Lower; Nasdaq Down 100 Points
U.S. stocks traded slightly lower this morning, with the Nasdaq Composite dropping around 100 points on Monday.
Recap: Viking Therapeutics Q3 Earnings
Viking Therapeutics (NASDAQ:VKTX) reported its Q3 earnings results on Wednesday, October 26, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
Earnings Scheduled For July 27, 2022
Companies Reporting Before The Bell
• Equinor (NYSE:EQNR) is projected to report earnings for its second quarter.
Viking Therapeutics Earnings Preview
Viking Therapeutics (NASDAQ:VKTX) is set to give its latest quarterly earnings report on Wednesday, 2022-07-27. Here's what investors need to know before the announcement.
Analysts estimate that Viking Therapeutics will report an earnings per share (EPS) of $-0.21.
Recap of Tuesday’s Biotech Catalysts – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy.
FDA Lifts Clinical Hold On Viking Therapeutics’ Rare Metabolic Disorder Study
The FDA has lifted the clinical hold placed on Viking Therapeutics Inc’s (NASDAQ:VKTX) trial of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD). …